Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TempraMed TechnologiesFRA:9DY +1.40%10 EBIT per Share is €-0.07 as of Mar. 2026. GuruFocus rates FRA:9DY with a GF Score™ of 10/100. The stock has 5 warning signs investors should review. Among 685 Medical Devices & Instruments companies, TempraMed Technologies ranks worse than 145985.26% on this metric.
TempraMed Technologies's EBIT per Share for the
three
months ended in Mar. 2026 was €-0.03.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.07.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for TempraMed Technologies's EBIT per Share or its related term are showing as below:
FRA:9DY's 3-Year EBIT Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 9.6 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
TempraMed Technologies (FRA:9DY) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
TempraMed Technologies EBIT per Share Related Terms
TempraMed Technologies EBIT per Share Historical Data
* Premium members only.
The historical data trend for TempraMed Technologies's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.07
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TempraMed Technologies (FRA:9DY) has a EBIT per Share of €-0.07 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on TempraMed Technologies and its competitors. According to the industry distribution chart, TempraMed Technologies ranks #999999 out of 685 companies in the Medical Devices & Instruments industry.
Is TempraMed Technologies' EBIT per Share too high?
TempraMed Technologies' current EBIT per Share is €-0.07. Based on the distribution chart, TempraMed Technologies ranks #999999 out of 685 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, TempraMed Technologies has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does TempraMed Technologies' EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, TempraMed Technologies ranks #999999 out of 685 companies for EBIT per Share. This places TempraMed Technologies in the lower half of its industry. The industry median EBIT per Share is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on TempraMed Technologies and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TempraMed Technologies's current EBIT per Share is €-0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TempraMed Technologies stock overvalued right now?
TempraMed Technologies (FRA:9DY) has a current EBIT per Share of €-0.07. The current EBIT per Share is €-0.07. TempraMed Technologies' overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For TempraMed Technologies (FRA:9DY), the current EBIT per Share is €-0.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TempraMed Technologies Ltd through its subsidiary, engaged in developing patent-protected technology designed to serve a broad range of medical and consumer products. TempraMed's primary focus is revolutionizing storage and management of injectable for temperature-sensitive medications. This inventive technology ensures adequate temperature storage conditions to medications without requiring power source or human intervention for years.
10GF Score
Get the complete analysis for FRA:9DY
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9DY has been successfully added to your 
